Zola-cel Death Raises the Bar for Bristol Myers' MS Program

Bristol Myers Squibb disclosed a patient death after the data cutoff in Breakfree-2, an early study of the experimental CAR T therapy zolacabtagene autoleucel, or zola-cel, for multiple sclerosis. The event raises the standard the company must meet before regulators and investigators can support restarting enrollment.

The patient had highly active relapsing multiple sclerosis and developed delayed motor symptoms after receiving zola-cel. Bristol Myers said the symptoms were not classified as immune effector cell-associated neurotoxicity syndrome, known as ICANS, and did not improve with intermittent corticosteroids or intravenous immunoglobulin. After doctors administered high-dose immunosuppressive treatment, the patient developed septic pneumonia and died the following day, 44 days after the cell infusion.

That sequence does not by itself establish one cause. Reuters reported that the patient's complications and extensive prior treatment made the underlying cause difficult to determine. The death also occurred after Bristol Myers had already paused enrollment. The company had voluntarily halted its zola-cel autoimmune studies in September while it reviewed neurological safety events, and it is working with the Food and Drug Administration on a path to restart. Reuters said the company is targeting early 2027.

Breakfree-2 enrolled 66 people whose disease remained active or whose disability worsened despite prior treatments. Safety was the primary endpoint. Cytokine release syndrome occurred in 42.4% of participants and ICANS in 7.6%, with nearly all cases resolving within days. Bristol Myers said a more serious ICANS event in a patient with progressive MS resolved within four days. Across the broader early-stage zola-cel autoimmune program, which had treated 190 patients, the company reported no other deaths.

The preliminary efficacy signals explain why the program still matters. All 60 patients who received the higher dose remained off their regular multiple-sclerosis drugs at the latest assessment, including nine followed for more than a year. Among patients with at least six months of follow-up, six of seven with highly active relapsing MS had no evidence of disease activity. All eight evaluable relapsing patients had stable or improved disability scores. In the progressive-MS group, 22 of 24 patients had stable or improved disability, and no new MRI lesions were observed.

Those results are encouraging, but they come from a small, uncontrolled early study and cannot settle the benefit-risk question. The key issue is not whether zola-cel can produce biological activity. It is whether Bristol Myers can identify the factors behind the neurological events and the death, define which patients are most vulnerable, and show that manufacturing or treatment changes reduce the risk without weakening efficacy.

Bristol Myers shares fell about 2% on October 23 after the disclosure. That move is modest relative to the clinical uncertainty because zola-cel is still experimental and the company's value is spread across a broad portfolio. Even so, the event can affect development timelines, trial costs and confidence in the wider autoimmune CAR T strategy.

Before assigning much value to the program, investors should look for a clear FDA-endorsed restart plan, updated investigator assessments of causality, detailed monitoring rules and evidence that any proposed change addresses the observed safety pattern. Until then, the efficacy data support continued research, not a conclusion that the program's risk has been resolved.